INTRODUCTION
Sulindac, a derivative of an indene acetic acid (indomethacin is an indole-acetic acid derivative), is a relatively new non-steroidal anti-inflammatory drug (NSAID). Its actions, characteristic for this group, include analgesia, anti-inflammatory and antipyretic activity. Sprain and strain injuries undoubtedly have an inflammatory component during the acute phase and logically lend themselves to treatment with NSAIDs in the hope of bringing about rapid relief of pain and inflammation and consequently improved function. Ibuprofen a nonsteroidal anti-inflammatory drug has been shown to be effective in such cases as Muckle (1974) ; sulindac, however, has never been assessed in this area. It was therefore decided to study the relative merits of sulindac and ibuprofen in the treatment of sprains and strains, when used in clinical practice as an adjunct to conventional physical therapy. Most soft tissue injuries in the UK are seen and treated by family physicians and/or Accident and Emergency Departments. A large study in patients from general practice would require the cooperation of many general practitioners. This obviously introduces the inherent problems of multi-observers (Grayson, 1977) 
PATIENTS AND METHODS
Males over the age of 18 years with a diagnosis of acute unilateral sprains or strains of the ankle, hips, shoulders or knees based upon history and physical findings, who presented themselves to the Royal Military Academy Hospital at Sandhurst within 48 hours of onset were considered eligible for the study. Patients were excluded if they had only mild pain at the first examination, fracture or suspicion of fracture subsequently confirmed by X-ray, of any contraindication to the use of either drug as stated in the data sheets.
Patients satisfying the entry criteria were allocated, using a predetermined randomised schedule, to receive either sulindac (Clinoril) 200 mg twice daily or ibuprofen (Brufen) 400 mg three times daily for a period of 4 days. No concomitant anti-inflammatory agent or treatments other than those shown in Table I were permitted during the trial period. (Table VI) show that preference is divided equally between the two drugs over the different measures of efficacy. The improvement score is reflected in both the patient's and physician's overall evaluation of treatment (Table VII and ViIl). 
